Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. November 2025 16:02 ET | Quelle: NurExone Biologic Inc

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its...
08. Oktober 2025 08:30 ET | Quelle: NurExone Biologic Inc

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing...
21. Januar 2025 16:20 ET | Quelle: NurExone Biologic Inc

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
27. März 2024 17:05 ET | Quelle: NurExone Biologic Inc

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise